Jinwon Life Sciences Subsidiary VGXI Plans Completion Ceremony on October 7

[Asia Economy Reporter Jang Hyowon] GenOne Life Sciences announced on the 18th that its subsidiary VGXI, a plasmid DNA contract development and manufacturing organization (CDMO), will hold a completion ceremony for its new factory built in Deison Technology Park, Conroe City, Texas, USA, on October 7.

According to GenOne Life Sciences, the new factory is equipped with four separate manufacturing trains and features state-of-the-art production equipment with flexible fermentation capacity exceeding 3000L, as well as expanded GMP filling and finishing capabilities. The new factory is planned to serve as VGXI's new headquarters and includes a dedicated area for small-scale rapid production services for customized therapies and mRNA.

The company stated, "Verification activities for the new factory are currently underway, and the existing factory will continue to be responsible for the commercial production of high-quality plasmid DNA."

Park Younggeun, CEO of GenOne Life Sciences, said, "The new VGXI headquarters is ready to support customers in achieving successful Phase 3 clinical trials and commercial launches of their products," emphasizing, "Based on accumulated expertise and highly skilled technology, VGXI will continue to meet the growing industry demand for next-generation pharmaceuticals."